- Home
- RVLV vs CANF Comparison
RVLV vs CANF Comparison
Compare RVLV & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVLV
- CANF
- Stock Information
- Founded
- RVLV 2003
- CANF 1994
- Country
- RVLV United States
- CANF Israel
- Employees
- RVLV N/A
- CANF N/A
- Industry
- RVLV Catalog/Specialty Distribution
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- RVLV Consumer Discretionary
- CANF Health Care
- Exchange
- RVLV Nasdaq
- CANF Nasdaq
- Market Cap
- RVLV N/A
- CANF 7.9M
- IPO Year
- RVLV 2019
- CANF N/A
- Fundamental
- Price
- RVLV $20.47
- CANF $1.15
- Analyst Decision
- RVLV Buy
- CANF Strong Buy
- Analyst Count
- RVLV 14
- CANF 2
- Target Price
- RVLV $28.79
- CANF $14.00
- AVG Volume (30 Days)
- RVLV 1.6M
- CANF 420.2K
- Earning Date
- RVLV 05-06-2025
- CANF 05-06-2025
- Dividend Yield
- RVLV N/A
- CANF N/A
- EPS Growth
- RVLV 81.03
- CANF N/A
- EPS
- RVLV 0.70
- CANF N/A
- Revenue
- RVLV $1,129,911,000.00
- CANF $674,000.00
- Revenue This Year
- RVLV $10.98
- CANF $461.72
- Revenue Next Year
- RVLV $8.77
- CANF N/A
- P/E Ratio
- RVLV $29.35
- CANF N/A
- Revenue Growth
- RVLV 5.73
- CANF N/A
- 52 Week Low
- RVLV $14.88
- CANF $1.22
- 52 Week High
- RVLV $39.58
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- RVLV 46.48
- CANF 36.96
- Support Level
- RVLV $19.72
- CANF $1.13
- Resistance Level
- RVLV $21.40
- CANF $1.27
- Average True Range (ATR)
- RVLV 1.39
- CANF 0.12
- MACD
- RVLV 0.28
- CANF -0.02
- Stochastic Oscillator
- RVLV 51.48
- CANF 2.90
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).